#Bioretec #Finland #Tampere #RemeOs #Activa

Bioretec Ltd Introduces New Stock Option Plan

On June 1, 2026, Bioretec Ltd's Board of Directors took a significant step in enhancing its employee engagement and commitment by approving a new stock option plan. This initiative is designed specifically for key personnel and selected consultants within the Group, aimed at fostering long-term dedication and financial returns through improved shareholder value.

Purpose of the Plan

The foundational goal of this stock option plan is to create a robust incentive system for around 30 integral employees and consultants. By offering stock options, Bioretec seeks to strengthen the collective focus on long-term performance, aligning interests between the company's workforce and its shareholders.

Details of the Stock Options

A total of 182,970,807 stock options will be issued under this plan, allowing holders the right to acquire either new or existing shares in Bioretec Ltd. Specifically, these options are classified as 2026A and 2026B, with 96,059,674 and 86,911,133 options allocated respectively. The gratuitous issuance of these options signifies Bioretec’s commitment to both its employees and the overarching goal of bolstering shareholder returns.

Once the stock options are fully exercised, they could represent up to 12% of the company's total shares and votes, should new shares be issued. The gradual vesting of options is structured over four years, with a cliff period of 12 months. During this period, 40% of the 2026A options and 25% of the 2026B options will become accessible, further enhancing the motivation for sustained employment.

Financial Impact

The pricing for these stock options is set at the volume-weighted average share price of Bioretec's stock from the prior month, increased by a 20% premium. This approach not only links the stock option's value to the company's performance but also ensures that the capital generated through option exercises will add to the invested unrestricted equity reserve. With an estimated market value of EUR 0.0172 per option, the total theoretical market value of the plan is approximately EUR 3,147,098, calculated using the Black-Scholes model.

Strategic Vision

This stock option plan is part of Bioretec’s broader strategy to refine its operational framework and motivate its team. The authorization for this initiative was granted during the Extraordinary General Meeting of Shareholders held in March 2026, showcasing the company’s proactive stance in creating a conducive work environment and maintaining a competitive edge in the medical device industry.

About Bioretec

Bioretec Ltd is a leading Finnish medical device company dedicated to revolutionizing orthopedic care through its innovative biodegradable implant technologies. With a commitment to advancing orthopedic treatment, Bioretec is actively involved in enhancing bone growth and accelerating fracture healing with its unique formulations, utilized in approximately 40 countries globally.

The company’s latest product line, RemeOs™, introduces advanced materials designed for optimal surgical outcomes, while its Activa line provides fully bioabsorbable implants cleared for a myriad of clinical applications. This focus on healing through absorption paves the way for more patient-friendly surgical solutions, emphasizing Bioretec’s mission to reshape orthopedic care.

For more information, please visit Bioretec's official website.